Cited 0 times in Scipus Cited Count

Analysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: a retrospective nationwide cohort study

DC Field Value Language
dc.contributor.authorKim, TH-
dc.contributor.authorAhn, MS-
dc.contributor.authorChoi, YW-
dc.contributor.authorKang, SY-
dc.contributor.authorChoi, JH-
dc.contributor.authorLee, HW-
dc.contributor.authorPark, M-
dc.contributor.authorKim, H-
dc.date.accessioned2023-02-13T06:23:23Z-
dc.date.available2023-02-13T06:23:23Z-
dc.date.issued2022-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/24563-
dc.description.abstractBACKGROUND: One-year S-1 or six-month capecitabine/oxaliplatin (CAPOX) has been the standard adjuvant chemotherapy for gastric cancer (GC). We investigated outcomes according to the cycles of adjuvant chemotherapy, using data from the Korean Health Insurance and Assessment Service. METHODS: A total of 20,552 patients, including 13,614 patients who received S-1 and 6,938 patients who received CAPOX extracted from 558,442 patients were retrospectively analyzed. The five-year overall survival rate was evaluated according to the duration of adjuvant chemotherapy. RESULTS: The five-year overall survival rate gradually increased according to the increase in adjuvant chemotherapy cycles in both the S-1 (/= 8 cycles: 77.9%) and the CAPOX groups (/= 8 cycles: 67.2%). CONCLUSIONS: Reducing the treatment cycles of adjuvant chemotherapy in GC with S-1 or CAPOX showed inferior survival outcomes. Completing the standard duration of adjuvant chemotherapy with S-1 or CAPOX would be strongly recommended.-
dc.language.isoen-
dc.subject.MESHAntineoplastic Combined Chemotherapy Protocols-
dc.subject.MESHCapecitabine-
dc.subject.MESHChemotherapy, Adjuvant-
dc.subject.MESHCohort Studies-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFluorouracil-
dc.subject.MESHHumans-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHOrganoplatinum Compounds-
dc.subject.MESHOxaliplatin-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHStomach Neoplasms-
dc.subject.MESHTreatment Outcome-
dc.titleAnalysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: a retrospective nationwide cohort study-
dc.typeArticle-
dc.identifier.pmid36057562-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440578-
dc.subject.keywordAdjuvant-
dc.subject.keywordChemotherapy-
dc.subject.keywordGastric cancer-
dc.subject.keywordNationwide cohort study-
dc.subject.keywordSurvival-
dc.contributor.affiliatedAuthorKim, TH-
dc.contributor.affiliatedAuthorAhn, MS-
dc.contributor.affiliatedAuthorChoi, YW-
dc.contributor.affiliatedAuthorKang, SY-
dc.contributor.affiliatedAuthorChoi, JH-
dc.contributor.affiliatedAuthorLee, HW-
dc.type.localJournal Papers-
dc.identifier.doi10.1186/s12885-022-10006-7-
dc.citation.titleBMC cancer-
dc.citation.volume22-
dc.citation.number1-
dc.citation.date2022-
dc.citation.startPage948-
dc.citation.endPage948-
dc.identifier.bibliographicCitationBMC cancer, 22(1). : 948-948, 2022-
dc.identifier.eissn1471-2407-
dc.relation.journalidJ014712407-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Files in This Item:
36057562.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse